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Edited by Judit Ova´diAbstract The formation of ﬁbrils by amyloid b-protein (Ab) is
considered as a key step in the pathology of Alzheimer’s disease
(AD). Inhibiting the aggregation of Ab is a promising approach
for AD therapy. In this study, we used biocompatible nanogels
composed of a polysaccharide pullulan backbone with hydropho-
bic cholesterol moieties (cholesterol-bearing pullulan, CHP) as
artiﬁcial chaperones to inhibit the formation of Ab-(1–42) ﬁbrils
with marked amyloidgenic activity and cytotoxicity. The CHP-
nanogels incorporated up to 6–8 Ab-(1–42) molecules per parti-
cle and induced a change in the conformation of Ab from a
random coil to a-helix- or b-sheet-rich structure. This struc-
ture was stable even after a 24-h incubation at 37 C and the
aggregation of Ab-(1–42) was suppressed. Furthermore, the
dissociation of the nanogels caused by the addition of methyl-
b-cyclodextrin released monomeric Ab molecules. Nanogels
composed of amino-group-modiﬁed CHP (CHPNH2) with posi-
tive charges under physiological conditions had a greater inhibi-
tory eﬀect than CHP-nanogels, suggesting the importance of
electrostatic interactions between CHPNH2 and Ab for inhibit-
ing the formation of ﬁbrils. In addition, CHPNH2 nanogels pro-
tected PC12 cells from Ab toxicity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Artiﬁcial chaperones1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease, the hallmarks of which are the extraneuronal deposi-
tion of amyloid ﬁbrils and the formation of intraneuronal neu-
roﬁbrillary tangles [1,2]. The amyloid ﬁbrils are mainly
composed of a 39–42 amino acid residue protein referred to
as amyloid b-protein (Ab). Aggregation of the soluble AbAbbreviations: Ab, amyloid b-protein; AD, Alzheimer’s disease; CHP,
cholesterol-bearing pullulan; CHPNH2, amino-group-modiﬁed choles-
terol-bearing pullulan; MbCD, methyl-b-cyclodextrin; CD, circular
dichroism; ThT, thioﬂavin-T; SEC, size exclusion chromatography;
TEM, transmission electron microscopy; MTT, 3-(4,5-dimethyl-2-thi-
azolyl)-2,5-diphenyltetrazolium bromide; DMEM, Dulbecco’s modi-
ﬁed Eagle’s medium
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doi:10.1016/j.febslet.2006.11.009monomer into toxic oligomeric or ﬁbrillar species is considered
to be a critical step in the pathology of the disease. Thus,
reducing the level of Ab in the brain and inhibiting the aggre-
gation of Ab are promising strategies for AD therapy [2].
Various compounds such as peptides [3,4], antioxidants [5,6],
anti-inﬂammatory drugs [7], and antibodies [8,9] have been
reported to have inhibitory eﬀects on the aggregation of Ab.
Furthermore, antibodies against Ab reduce the level of the
protein in the brain of APP transgenic mice and inhibit neuro-
toxicity [10]. Passive and active immunizations are promising
strategies for AD therapy, although an unexpected meningoen-
cephalitis is a risk for application to humans [11].
Accumulating evidence indicates that molecular chaperones
play a crucial role in neurodegenerative diseases [12]. The
involvement of chaperone proteins in the pathology of AD
has been recently suggested using transgenicCaenorhabditis ele-
gans [13]. In vitro experiments also showed that small heat
shock proteins inhibit the formation of ﬁbrils by Ab [14]. Over-
expression of chaperones can suppress neurodegeneration in
cases of polyglutamine disease [12]. Molecular chaperones tran-
siently bind to exposed hydrophobic surfaces of unstable pro-
teins (folding intermediates or partially denatured proteins) to
prevent irreversible aggregation. To simulate the function of
molecular chaperones, we designed amphiphilic nanogels that
can incorporate proteins inside the gel [15,16]. Cholesterol-
bearing pullulan (CHP) composed of a backbone of polysac-
charide and hydrophobic cholesteryl moieties forms hydrogel
nanoparticles (nanogels) with a diameter of 20–30 nm by inter-
molecular self-association in aqueous solutions (Fig. 1) [17–19].
Four to ﬁve pullulan chains of 100 kDa are cross-linked
non-covalently by the association of 4–5 cholesteryl moieties.
Nanogels are biocompatible and have been applied for cosmet-
ics. Recent studies have revealed that CHP nanogels have a
molecular chaperone-like activity [20–22]: CHP nanogels form
complexes with thermally or chemically denatured proteins
and prevent their non-speciﬁc aggregation. Refolded proteins
are released from the complexes by addition of methyl-b-cyclo-
dextrin (MbCD), which binds to the cholesteryl moiety of CHP
and induces the dissociation of CHP nanogels (see Fig. 6B).
In this study, we applied the CHP nanogel as an artiﬁcial
chaperone system for controlling the aggregation and cyto-
toxicity of Ab-(1–42) with marked amyloidgenic activity and
neurotoxicity. Nanogels could eﬀectively incorporate Ab-
(1–42), thereby inhibiting amyloid ﬁbrils from forming, and
released monomeric Ab molecules on addition of MbCD. Fur-
thermore, nanogels composed of amino-group-modiﬁed CHP
(CHPNH2) (Fig. 1A) having positive charges showed a greater
inhibitory eﬀect than CHP nanogels and suppressed Abblished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structures of CHP and CHPNH2 (A) and schematic diagrams of the formation of nanogel particles (B).
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trostatic interactions.2. Materials and methods
2.1. Proteins
Human Ab-(1–42) labeled with a 7-diethylaminocoumarin-3-
barbonyl group at the N terminus (DAC-Ab-(1–42)) was custom syn-
thesized and characterized by Peptide Institute (Minou, Japan). The
dye-labeled protein was handled in light-protected, capped tubes under
a nitrogen atmosphere to avoid photodegradation. Unlabeled human
Ab-(1–42) was also purchased from Peptide Institute. The proteins
were dissolved in 0.02% ammonia on ice. We removed any aggregates
by ultracentrifugation in 500 lL polyallomer tubes at 540000 · g, 4 C
for 3 h. The supernatant was then mixed with an equal volume of dou-
ble concentrated buﬀer (20 mM Tris/300 mM NaCl/2 mM EDTA–
2Na, pH 7.4). The peptide concentration of the supernatant was deter-
mined in triplicate by Micro BCA protein assay (Pierce, Rockford, IL).
2.2. Nanogels
CHP was synthesized as reported previously [17]. Pullulan (MW =
1.0 · 105) was substituted with 1.4 cholesterol moieties (CHP).
CHPNH2 was synthesized by conjugation of ethylene diamine with
CHP [23]. CHPNH2 with 12 amino groups per 100 glucose units was
used in this study. CHP and CHPNH2 were suspended and swollen
in MilliQ-water with stirring for 12 h at 25 C to give a turbid
suspension. The suspended solutions were then sonicated using a
probe-type sonicator (Soniﬁer Model 250, Branson Ultrasonic Co.,
Ltd., tip diameter 2 mm) at 40 W for 15 min under cooling with ice.
The resulting suspension was ﬁltered through three diﬀerent types of
syringe ﬁlters (pore size 0.8, 0.45, and 0.22, Millipore Co., Ltd.) to
remove any impurities (dust, metal species from the soniﬁer or large
aggregates of hydrophobized polymers). Finally, a clear aqueous solu-
tion was obtained. The sizes of CHP and CHPNH2 nanogels were 29.1
and 29.6 nm, respectively, as determined by dynamic light scattering
(DLS, Zetasizer Nano-ZS, Malvern Instruments Ltd.).
2.3. Fluorescence
Fluorescence measurements were carried out on a Shimadzu RF-
5300 spectroﬂuorometer with a cuvette holder thermostated at 37 C.Reported spectra are those after the subtraction of the spectrum for
a blank (and volume correction in titration experiments).2.4. Fluorescence titration
The DAC-Ab-(1–42) solution (0.5 lM, 2 mL) was titrated with ali-
quots of a nanogel solution in a quartz cuvette with gentle stirring.
Fluorescence emission spectra were recorded at an excitation wave-
length of 415 nm. The titration interval was 3 min, which was con-
ﬁrmed to be suﬃcient for the establishment of binding equilibrium.2.5. Circular dichroism (CD)
Human Ab-(1–42) (15 lM) in buﬀer (10 mM Tris/150 mM/NaCl/
1 mM EDTA-2Na, pH 7.4) was used for CD measurements. CD spec-
tra were measured on a Jasco J-820 apparatus, using a 1-mm path
length quartz cell to minimize the absorbance due to buﬀer compo-
nents. The instrumental outputs were calibrated with non-hygroscopic
ammonium d-camphor-10-sulfonete [24]. Eight scans were averaged
for each sample. The averaged spectra for a blank (nanogel solution
or buﬀer) were subtracted.2.6. Aggregation assay
Native human Ab-(1–42) (15 lM) was incubated with nanogels in
buﬀer at 37 C for 24 h and the aggregation was monitored by size-
exclusion chromatography (SEC) [25] and thioﬂavin T (ThT) assay
[26,27], and transmission electron microscopy (TEM).
The protein was fractionated with a Superdex 75 10/300 GL column
with an exclusion limit 42000 Da (Amersham Biosciences), which had
been pretreated with an excess of BSA to block the non-speciﬁc binding
of proteins. The column was eluted with PBS, pH 7.4, at a ﬂow rate of
0.5 mL/min and the protein was detected by measuring UV absorbance
at 220 nm. Each sample was centrifuged at 10000 · g for 10 min and the
supernatant (25 lL) was injected. Molecular mass was estimated with
FITC-dextrans (MW 4400, 21200 and 42000) as standards.
The ThT assay was carried out as follows. The sample (ﬁnal concen-
tration, 0.5 lM) was added to a 5 lM ThT solution in 50 mM glycine
buﬀer (pH 8.5). Fluorescence at 490 nm was measured at an excitation
wavelength of 446 nm at 25 C. A calcein solution (1 lM) in 10 mM
Tris/150 mM NaCl/1 mM EDTA (pH 7.4) buﬀer was used as a stan-
dard.
To estimate the extent of aggregation of Ab-(1–42) incorporated
into nanogels, 5 mM MbCD was added before the SEC and ThT as-
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cholesterol moieties that provide cross-linking domains in the nanogels
[21].
TEM experiments were carried out by Ultrastructure Research Insti-
tute, Hanaichi Co. Ltd, Okazaki, Japan. Samples were spread on car-
bon-coated grids, negatively stained with uranium acetate, and
examined under a JEOL 1200 EX electron microscope with accelera-
tion voltage of 100 kV.
2.7. Cell viability assay
Rat pheochromocytoma PC12 cells were cultured in DMEM (Dul-
becco’s modiﬁed Eagle’s medium) containing 5% horse serum, 10% bo-
vine serum, 100 units/mL penicillin, and 0.1 mg/mL streptomycin at
37 C with 5% CO2. The materials were purchased from Invitrogen
(Carlsbad, CA). Cell viability was estimated by the 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay [28,29].
After plated at a density of 5000 cells/well onto a Biocoat poly-D-ly-
sine-coated 96-well plate (Becton Dickinson, England), cells were incu-
bated for 24 h at 37 C with 5% CO2. After removal of the medium, an
Ab-(1–42) solution (15 lM) that had been incubated for 24 h at 37 C
with or without CHPNH2 nanogels (60 mM as glucose) in Tris buﬀer
(pH 7.4) was diluted to 1 lMwith the medium and applied to each well
(100 lL). After a 24-h incubation, 10 lL of 0.5% MTT (Nacalai Tes-
que, Kyoto) in Tris buﬀer was added to the cell culture, which was sub-
sequently incubated for 5 h. One hundred lL of 20% SDS solution in
0.01 M HCl was added and the samples were incubated overnight at
37 C. The absorbance at 595 nm was measured. The absorbance of
the cells that had been treated only by the vehicle was set to 100% via-
bility.Fig. 2. Binding of DAC-Ab-(1–42) to nanogels at 37 C. Fluorescence
spectra of DAC–Ab(1–42) were recorded in buﬀer with CHP (A) and
CHPNH2 (B) nanogels at glucose-to-protein ratios of 0, 40, 160, 320,
640, and 2560 from the bottom. Relative ﬂuorescence enhancement,
R = (F  F0)/F0, is plotted as a function of the glucose unit-to-protein
ratio (C). Fluorescence intensity at 466 nm in the presence and absence
of nanogels is denoted by F and F0, respectively. Standard deviations
for two preparations are shown by error bars. Solid lines indicate the
ﬁtting curves calculated with Eq. (4).3. Results
3.1. Incorporation of DAC-Ab-(1–42) into nanogels
The incorporation of DAC-Ab-(1–42) into two types of
nanogel particles was assessed on the basis of the ﬂuorescence
of DAC [30,31]. The DAC ﬂuorophore is practically non-ﬂuo-
rescent in aqueous environments, but its ﬂuorescence intensi-
ties greatly increase in hydrophobic environments such as
membranes. The addition of CHP-nanogels (Fig. 2A) or
CHPNH2-nanogels (Fig. 2B) increased DAC-Ab-(1–42) ﬂuo-
rescence in a dose-dependent manner accompanied by a blue
shift in the emission maximum from 483 to 466 nm. As a quan-
titative measure, relative ﬂuorescence enhancement, R, is de-
ﬁned as follows:
R ¼ ðF  F 0Þ=F 0: ð1Þ
Fluorescence intensity at 466 nm in the presence and absence
of nanogels is denoted by F and F0, respectively. Fig. 2C plots
the R value as a function of the glucose unit-to-protein ratio.
The curves were analyzed as follows. The ratio of R to the
maximum value of R (Rmax) gives the bound fraction of the
peptide at each data point. Therefore, the amount of bound
DAC-Ab-(1–42) per glucose unit of the nanogel (x) and free
DAC-Ab-(1–42) concentration (cf) are expressed as functions
of R/Rmax and glucose unit/DAC-Ab-(1–42).
x ¼ R=Rmax  ½Ab=½glucose unit; ð2Þ
cf ¼ ½Ab  ð1 R=RmaxÞ: ð3Þ
The binding equilibrium can be expressed by Langmuir’s equa-
tion [30,31].
x ¼ xmaxKcf=ð1þ KcfÞ: ð4Þ
The maximal x value was denoted by xmax. The ﬁtting curves
in Fig. 2C were obtained by substituting Eqs. (2) and (3) into
Eq. (4). The binding parameters obtained are summarized inTable 1. In binding aﬃnity (K) and binding capacity (xmax),
the two types of nanogels were very similar, however the Rmax
value was larger for CHP than for CHPNH2.
3.2. Secondary structure
The conformation of Ab-(1–42) in the absence and presence
of the nanogels was estimated from CD spectra (trace 1 in
Table 1
Parameters for binding of DAC-Ab to nanogels at 37 Ca
Nanogels Rmax K
(107 M1)
xmax
(Ab/glucose, mol/mol)
CHP 12.27 ± 0.19 2.62 ± 1.01 0.00272 ± 0.00019
CHPNH2 9.63 ± 0.20 2.87 ± 1.61 0.00298 ± 0.00025
aBinding parameters (the means ± S.D., n = 2) were estimated from
Eq. (4).
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structure. The protein was conﬁrmed to be almost entirely
monomeric by SEC (Fig. 4A) and ThT assay (data not shown).
At a lower glucose unit/Ab ratio of 500 in both the CHP
(Fig. 3B) and CHPNH2 (Fig. 3D) systems, the spectra exhib-
ited a shallow minimum around 218 nm, reminiscent of b-
sheets. In contrast, the protein adopted a helix-rich structure
at a higher glucose unit/Ab ratio of 4000 as suggested by dou-Fig. 3. CD spectral changes of Ab-(1–42) in nanogels. CD spectra of the pro
and CHPNH2 (D, E) nanogels at a glucose unit/Ab ratio of 500 (B, D) or 4ble minima around 208 and 222 nm (Fig. 3C and E). CD spec-
tra were also measured after a 24-h incubation (trace 2 in
Fig. 3). In the absence of a nanogel, Ab-(1–42) adopted a b-
sheet rich structure (Fig. 3A). In the presence of small amounts
of the CHP-nanogel, the b-sheet structure grew (Fig. 3B),
whereas the a-helix structure was maintained at a higher glu-
cose-to-protein ratio of 4000 (Fig. 3C). In contrast, CD spectra
did not change even after 24 h of incubation with small
amounts of the CHPNH2-nanogel (Fig. 3D).
3.3. Aggregation assay
The amyloid ﬁbril formation of Ab-(1–42) incorporated into
nanogels was estimated on the basis of SEC and ThT ﬂuores-
cence. A major peak of monomeric Ab was observed at 28 min
for freshly prepared Ab-(1–42), whereas no monomer was de-
tected after a 24-h incubation indicating that all Ab molecules
aggregated into ﬁbrils (Fig. 4A). Fibrils had been removed bytein were recorded at 37 C without a nanogel (A) or with CHP (B, C)
000 (C, E). Incubation time: trace 1, 0 h; trace 2, 24 h.
Fig. 4. Aggregation of Ab-(1–42) in nanogels. SEC analysis of Ab-(1–42) in the absence (A) or presence (B) of CHP-nanogels (glucose unit/
Ab = 4000) with or without a 24-h incubation at 37 C. Ab-(1–42) (15 lM) was incubated with various amounts of CHP (C) or CHPNH2 (D)
nanogel for 24 h. ThT ﬂuorescence at 490 nm (excitation at 446 nm) was measured, and expressed relative to the ﬂuorescence intensity of Ab-(1–42)
incubated without a nanogel (circles). The population of Ab monomer was estimated from the peak intensity of SEC (squares). The peak intensity of
the 0 h sample in Fig. 4A was set to 100%.
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sistent with this, a signiﬁcant increase in ThT ﬂuorescence
was observed, suggesting amyloid ﬁbrils had formed. The
dye selectively binds to amyloid ﬁbrils with an accompanying
increase in ﬂuorescence intensity [26,27]. In the presence of
CHP- or CHPNH2-nanogels, ThT ﬂuorescence decreased in
intensity in a dose-dependent manner (Fig. 4C and D), sug-
gesting that the formation of ﬁbrils was suppressed by interac-
tion of Ab with the nanogels. CHPNH2-nanogels markedly
decreased ThT ﬂuorescence compared to CHP-nanogels: A
glucose unit/Ab ratio of 250 was suﬃcient to suppress the ﬂuo-
rescence to 20%, whereas a much higher ratio, 4000, was re-
quired in the case of CHP-nanogels. The protective eﬀect of
CHPNH2 nanogels was also conﬁrmed by TEM. Without
nanogels, amyloid ﬁbrils with a width of 6–12 nm and a length
of 200–300 nm were observed after a 24-h incubation
(Fig. 5A). In contrast, no amyloid ﬁbrils were observed in
the presence of CHPNH2 (Fig. 5B). The recovery of the Ab
monomer from nanogel particles on addition of MbCD was
evaluated by SEC. Even without incubation, only 30% of
monomeric Ab was recovered in the presence of large amounts
of the CHP-nanogel (Fig. 4A and B), suggesting interaction
between Ab and dissociated nanogels. However, almost the
same amount of monomeric Ab was recovered after a 24-h
incubation, indicating that the nanogels prevented Ab from
aggregating, consistent with the results of the ThT assay. At
lower glucose unit/Ab values, the eﬃciency of the recoverywas reduced (Fig. 4C). In contrast, CHPNH2-nanogels were
more eﬀective, a maximal recovery of 20–30% being achieved
at glucose/Ab values above 1000 (Fig. 4D).
3.4. Cytotoxicity assay
The cytotoxicity of Ab-(1–42) was examined by the MTT
assay (Fig. 5C). Aggregated Ab exerted a toxic eﬀect against
PC12 cells even at a low concentration of 1 lM. The cell via-
bility was decreased to 22%. In contrast, the co-existence of
CHPNH2 nanogels signiﬁcantly reduced the toxicity of Ab
and recovered the viability to 82% at a glucose-to-protein ratio
of 4000. These observations indicate that CHPNH2 nanogels
eﬀectively incorporated Ab molecules even in the presence of
serum proteins in the medium and inhibited the aggregation
of Ab. Furthermore, it should be noted that nanogels them-
selves had no harmful eﬀects.4. Discussion
CHP-nanogels can internalize heat-denatured proteins and
prevent thermal aggregation like molecular chaperones
[20,21]. We used this system to inhibit the formation of ﬁbrils
and cytotoxicity of Ab-(1–42). Nanogels composed of CHP
and amino-group-modiﬁed CHP (CHPNH2) incorporated
unordered monomeric Ab molecules (Fig. 2). There is no dif-
ference in binding parameters (K and xmax) between CHP
Fig. 5. TEM images of 24-h incubated Ab-(1–42) (15 lM) without (A) or with (B) CHPNH2 nanogels at a glucose-to-Ab ratio of 4000 (scale
bar = 100 nm). Allow heads show nanogel particles. (C) Cytotoxicity of 24-h incubated Ab-(1–42) against PC12 cells as determined by the MTT
assay (n = 6, ±S.E.). The ﬁnal concentrations of Ab and CHPNH2 nanogels were 1 lM and 4 mM (as glucose), respectively.
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CHPNH2 are not critical for the binding to Ab. The smaller
Rmax value for CHPNH2 may be due to the quenching ability
of amines [31]. One nanogel particle consists of 2000–2500 glu-
cose units. Therefore, the binding capacity (0.0027–0.0030 Ab
molecules per glucose unit) indicates that nanogels can inter-
nalize 6–8 Ab molecules per particle. The binding aﬃnity val-
ues indicate that >90% of unlabeled Ab molecules are
incorporated into nanogels above a glucose unit/Ab value of
500, even if the fact that the introduction of the DAC moiety
increases the binding constant by 40-fold [30] is taken into ac-
count. Thus, 6 molecules are present per particle at a glucose
unit/Ab value of 500, whereas on average, each particle con-
tains only one protein molecule at a glucose unit/Ab value of
4000 (Fig. 6).
We previously showed that Ab binds to a GM1 ganglioside
cluster, but not to non-clustered GM1 or cholesterol at a phys-
iological pH and ionic strength [30,32]. Ab also binds to gly-
cosaminoglycans, a component of the extracellular matrix
[33]. These ﬁndings suggest that clustered sugar molecules
are important for interaction with Ab. The wavelengths of
emission maxima (466 nm, Fig. 2A and B) were identical to
those in GM1 clusters [30], indicating that the N-terminus is
located in a similar environment i.e. sugar clusters.
The Ab molecules incorporated into nanogel particles chan-
ged from a random coil to a-helix or b-sheet structure, as indi-
cated by CD measurements (Fig. 3). An increase in protein
density in nanogel particles (with a decrease in glucose unit/Ab ratio from 4000 to 500) induces an a-helix-to-b-sheet tran-
sition (Fig. 6). Similar structural changes were observed in Ab-
(1–40) bound to GM1- or GT1b-containing membranes [30,32]
and phosphatidylglycerol bilayers [34]. The CD spectrum of
Ab without a nanogel changed from that of a random coil
to one of a b-sheet-rich structure accompanied by an increase
in ThT ﬂuorescence after a 24-h incubation at 37 C (Figs. 3
and 4), suggesting that amyloid ﬁbrils were generated. The
presence of even smaller amounts of nanogel inhibited the
ﬁbrillation with CHPNH2 exhibiting stronger eﬀects, although
the protein assumed a b-sheet rich structure. It should be noted
that the structure is somewhat diﬀerent from that of ﬁbrils
formed in the absence of nanogels: The minima of the ﬁbril
CD spectrum is red shifted by 2 nm (Fig. 3). Therefore, smaller
amounts of nanogels appear to sequester several Ab molecules
in a particle, imposing a non-ﬁbrillar b-sheet conformation
and inhibiting the formation of ﬁbrils (Fig. 6). In striking con-
trast, the binding of Ab to GM1-containing raft-like mem-
branes facilitated ﬁbrillation under conditions where b-sheets
are formed [32]. The b-sheet on the membrane surface acts
as a template for amyloid ﬁbrils.
In the presence of large amounts of nanogels, where each
particle contains one protein molecule, Ab-(1–42) maintained
an a-helical structure and exhibited less than 15% ThT ﬂuores-
cence even after a 24-h incubation (Fig. 4), suggesting that the
nanogels eﬀectively suppressed the aggregation of Ab-(1–42)
(Fig. 6). An increase in a-helix content with incorporation into
nanogels was reported for b-sheet proteins such as a-chymo-
Fig. 6. Schematic representation of the interaction between nanogel chaperones and the Ab protein (A) and release of trapped Ab from nanogels by
MbCD (B).
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proteins remained colloidally stable without aggregating even
at high temperature.
The Ab internalized into nanogels was released with the
addition of MbCD. The amount of monomeric Ab released
was less than 30% of all Ab even at a glucose unit/Ab of
4000, because Ab directly bound to dissociated nanogel parti-
cles as indicated by the SEC experiments (Fig. 4B). The obser-
vation that oligomers were not detected by SEC indicates that
Ab was present as a monomer or oligomers that can be easily
dissociated into monomers upon the disintegration of nanogel
particles. Molecular chaperones such as GroEL selectively trap
unstable proteins in a nanosize cage, preventing irreversible
aggregation. With the aid of ATP and another co-chaperone,
the host chaperone then releases the protein in its native form.
As artiﬁcial chaperones, nanogels comparable in size to pro-
teins are useful for the eﬀective trapping of Ab monomers
(or oligomers) without aggregation. Nanogels are shielded
from aberrant interactions with other nearby Ab moleculesby the trapping of the Ab inside the nanosize gel matrix.
Moreover, with the addition of MbCD, the trapped Ab is re-
leased as a monomer without the formation of putative toxic
oligomers.
CHPNH2-nanogels had a greater inhibitory eﬀect on the
aggregation of Ab than CHP-nanogels (Figs. 3 and 4),
although the parameters for the binding of the two nanogels
with Ab were very similar (Table 1). A number of studies have
reported that electrostatic interactions are important for the
aggregation of Ab: A solid-state NMR study revealed that
an intramolecular salt bridge between Asp23 and Lys28 is
formed in the Ab-(1–40) ﬁbril and that a bend structure in
the region Asp23–Gly29 is stabilized by electrostatic interac-
tions of side chains [35]. Ab-(1–42) is also predicted to form
a similar bend structure in ﬁbrils [36,37]. Changes to the
charges of Glu22 [38] and metal ions such as Zn2+, Cu2+ and
Fe3+ [39,40] also enhance the formation of Ab ﬁbrils. Thus,
the positive charges of CHPNH2-nanogels may aﬀect those
interactions required for the aggregation of Ab.
6594 K. Ikeda et al. / FEBS Letters 580 (2006) 6587–6595The inhibition of Ab aggregation by non-cytotoxic CHP-
NH2 nanogels resulted in a signiﬁcant protective eﬀect against
the cytotoxicity of Ab (Fig. 5C), suggesting a possible applica-
tion to AD therapy. Nanogels can also be applied to immuno-
therapy. A number of studies have reported that nanoparticles
such as liposomes, polyesters, and polysaccharides are potent
vaccine adjuvants that incorporate an antigen and help
immune responses [41]. Recently, CHP-nanogels were also
found to be promising adjuvants for polyvalent vaccines [42–
44]. Furthermore, CHPNH2-nanogels have greater cellular up-
take eﬃciency than the cationic liposomes widely used in drug
delivery systems [21]. Another advantage of nanogels is that
they can control the conformation of Ab (Fig. 3). Therefore,
nanogel-Ab complexes are applicable for conformation-
speciﬁc vaccination.
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